RESEARCH - MTX associates with reduced prevalence of metabolic syndrome in RA patients over 60

[Guest guest]

Methotrexate Therapy Associates with Reduced Prevalence of the

Metabolic Syndrome in Rheumatoid Arthritis Patients Over the Age of

60- More than Just an Anti-inflammatory Effect? A Cross Sectional

Study

Tracey E Toms; Vasileios F Panoulas; Holly ; MJ ;

D Kitas

Posted 09 Feb 2010

Arthritis Research & Therapy. 2009;11(4):R110

Abstract

Introduction The metabolic syndrome (MetS) may contribute to the

excess cardiovascular burden observed in rheumatoid arthritis (RA).

The prevalence and associations of the MetS in RA remain uncertain:

systemic inflammation and anti-rheumatic therapy may contribute.

Methotrexate (MTX) use has recently been linked to a reduced presence

of MetS, via an assumed generic anti-inflammatory mechanism. We aimed

to: assess the prevalence of the MetS in RA; identify factors that

associate with its presence; and assess their interaction with the

potential influence of MTX.

**********************************************************

Read the full article here:

http://www.medscape.com/viewarticle/714736

Not an MD